Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

RESPONSE-2 is a phase 3 study comparing the efficacy and safety of ruxolitinib with the best available therapy (BAT) in hydroxyurea-resistant/hydroxyurea-intolerant polycythemia vera (PV) patients without palpable splenomegaly. This analysis evaluated the durability of the efficacy and safety of rux...

Descripción completa

Detalles Bibliográficos
Autores principales: Griesshammer, Martin, Saydam, Guray, Palandri, Francesca, Benevolo, Giulia, Egyed, Miklos, Callum, Jeannie, Devos, Timothy, Sivgin, Serdar, Guglielmelli, Paola, Bensasson, Caroline, Khan, Mahmudul, Ronco, Julian Perez, Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097748/
https://www.ncbi.nlm.nih.gov/pubmed/29804268
http://dx.doi.org/10.1007/s00277-018-3365-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097748/
https://www.ncbi.nlm.nih.gov/pubmed/29804268
http://dx.doi.org/10.1007/s00277-018-3365-y

Ejemplares similares